metadata/provenance.csv

provenance_id,source_id,source_title,source_type,doi_or_url,source_license_or_access,source_role,records_generated_from_source,source_pdf_redistributed,source_figures_or_tables_redistributed,generation_method,record_origin_default,output_license
PROV_MEMO_OLIGOTOX_PHASE2_ALIGNMENT,MEMO_OLIGOTOX_PHASE2_ALIGNMENT,DBbun OligoTox Phase 2 Alignment Memo,alignment_memo,internal_db_bun_alignment_memo,DBbun-authored working memo,governing_schema_and_rules,14,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_PNPLA3_ROMEO_VALENTI_2025,PNPLA3_ROMEO_VALENTI_2025,Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics,review_open_access,10.1111/liv.70240,Creative Commons Attribution,PNPLA3_precision_genetics_siRNA_ASO_therapeutic_targeting_context,16,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RAPIROSIRAN_SANYAL_2025,RAPIROSIRAN_SANYAL_2025,Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis,phase1_randomized_double_blind_clinical_open_access,10.1016/j.jhep.2025.05.031,CC BY 4.0,HSD17B13_GalNAc_siRNA_clinical_PK_PD_liver_safety_and_MASH_histology_context,56,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIVER_SPHEROID_SCHOLTEN_2026,LIVER_SPHEROID_SCHOLTEN_2026,A Long-Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc-Conjugated siRNAs,human_in_vitro_open_access,10.1111/cts.70536,Creative Commons Attribution,human_liver_spheroid_GalNAc_siRNA_screening,41,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RO7239958_GERETTI_2025,RO7239958_GERETTI_2025,"Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection",phase1_clinical_open_access,10.1128/aac.00679-25,CC BY 4.0,ASO_safety_PK_PD_transaminase_reference,38,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MOHAMED_NANOPARTICLE_HEPATITIS_2026,MOHAMED_NANOPARTICLE_HEPATITIS_2026,Nanoparticle approaches for hepatitis therapy and clinical translation,review_open_access_restricted_reuse,10.1186/s11671-026-04450-8,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt figures/tables/text,nanoparticle_delivery_hepatic_targeting_and_safety_context,13,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MENG_HYBRID_RNA_LNP_HCC_2025,MENG_HYBRID_RNA_LNP_HCC_2025,Reversal of tumour immune evasion via enhanced MHC-Class-I antigen presentation by a dual-functional RNA regulated system,research_open_access_restricted_reuse,10.1186/s12943-025-02480-x,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt figures/tables/text,hybrid_RNA_LNP_payload_architecture_and_liver_tumour_immunomodulation_context,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_CHEN_OVARIAN_MTTP_APOB_MIPOMERSEN_2025,CHEN_OVARIAN_MTTP_APOB_MIPOMERSEN_2025,Ovarian expression of functional MTTP and apoB for VLDL assembly and secretion in chickens,research_open_access,10.1016/j.psj.2025.104993,CC BY 4.0,APOB_ASO_mipomersen_lipid_export_and_lipotoxic_stress_context,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LU_SULT1B1_SE_MASLD_2026,LU_SULT1B1_SE_MASLD_2026,Super-enhancer-driven recruitment of C/EBPbeta by SULT1B1 is implicated in metabolic dysfunction-associated steatotic liver disease progression,research_open_access_restricted_reuse_article_in_press,10.1186/s13148-026-02121-0,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt figures/tables/text,MASLD_epigenetic_lipid_accumulation_SULT1B1_CEBPB_siRNA_context,11,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_OOSTVEEN_ANGPTL3_LIVER_SAFETY_2023,OOSTVEEN_ANGPTL3_LIVER_SAFETY_2023,Angiopoietin-like 3 inhibition and the liver: less is more?,review_open_access,10.1097/MOL.0000000000000898,CC BY 4.0,ANGPTL3_ASO_vs_siRNA_liver_safety_and_hepatic_fat_context,13,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ENGELBEEN_ALK4_MUSCLE_SIRNA_2023,ENGELBEEN_ALK4_MUSCLE_SIRNA_2023,Efficient Downregulation of Alk4 in Skeletal Muscle After Systemic Treatment with Conjugated siRNAs in a Mouse Model for Duchenne Muscular Dystrophy,research_open_access,10.1089/nat.2022.0021,CC BY 4.0,cholesterol_conjugated_siRNA_extrahepatic_delivery_tolerability_context,9,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KIM_MILASEN_CUSTOM_ASO_2019,KIM_MILASEN_CUSTOM_ASO_2019,Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease,n_of_1_clinical_brief_report,10.1056/NEJMoa1813279,NEJM copyrighted article; use as evidence/context only; do not reproduce source figures/tables/text,patient_customized_splice_modulating_ASO_design_safety_workflow_context,8,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KEATING_ASO_OBESITY_NAFLD_2022,KEATING_ASO_OBESITY_NAFLD_2022,Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease,mini_review_open_access,10.3389/fphys.2022.839471,CC BY 4.0,ASO_metabolic_NAFLD_targeting_delivery_chemistry_and_hepatotoxicity_challenges_context,15,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HAGEDORN_LNA_HEPATOTOX_RF_2013,HAGEDORN_LNA_HEPATOTOX_RF_2013,Hepatotoxic Potential of Therapeutic Oligonucleotides Can Be Predicted from Their Sequence and Modification Pattern,research_open_access,10.1089/nat.2013.0436,Mary Ann Liebert open-access article; use as evidence/context only; do not reproduce source figures/tables/text,sequence_modification_pattern_hepatotoxicity_prediction_context,27,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_GANE_VIR2218_ALNHBV_HBV_RNAI_2023,GANE_VIR2218_ALNHBV_HBV_RNAI_2023,Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials,preclinical_and_randomized_clinical_open_access_restricted_reuse,10.1016/j.jhep.2023.05.023,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt source figures/tables/text,GalNAc_siRNA_ESCplus_seed_region_offtarget_and_ALT_safety_context,18,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DUDZICZ_ZILEBESIRAN_HTN_REVIEW_2025,DUDZICZ_ZILEBESIRAN_HTN_REVIEW_2025,Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension,review_open_access,10.3390/jcm14207365,CC BY 4.0,zilebesiran_GalNAc_siRNA_AGT_RAAS_blood_pressure_durability_and_safety_monitoring_context,13,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HAUPTMANN_SIRNA_BULGES_GALNAC_2022,HAUPTMANN_SIRNA_BULGES_GALNAC_2022,Engineering miRNA features into siRNAs: Guide-strand bulges are compatible with gene repression,mechanistic_siRNA_design_open_access_restricted_reuse,10.1016/j.omtn.2022.02.004,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt figures/tables/text,guide_strand_bulge_tolerance_GalNAc_siRNA_offtarget_prediction_context,14,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_XIE_FBLL1_HCC_SPATIAL_MULTIOMICS_2026,XIE_FBLL1_HCC_SPATIAL_MULTIOMICS_2026,Integrated Multi-Omics and Spatial Transcriptomics Identify FBLL1 as a Malignant Transformation Driver in Hepatocellular Carcinoma,HCC_multiomics_spatial_transcriptomics_functional_siRNA_open_access,10.3390/cells15030246,CC BY 4.0,FBLL1_HCC_malignant_hepatocyte_spatial_context_and_siRNA_knockdown_growth_suppression_context,9,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZHAI_GALNAC_LNP_SIMKK4_LIVER_REGEN_2026,ZHAI_GALNAC_LNP_SIMKK4_LIVER_REGEN_2026,Dual targeted gene delivery strategy mediated by GalNAc-modified lipid nanoparticles enhances liver regeneration through specific knockdown of MKK4,GalNAc_LNP_siRNA_liver_regeneration_open_access,10.1016/j.mtbio.2026.103059,CC BY 4.0,GalNAc_modified_LNP_siMKK4_hepatocyte_targeting_liver_regeneration_ACLF_context,21,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WANG_OGT_SEV_LSEC_MASLD_2026,WANG_OGT_SEV_LSEC_MASLD_2026,OGT-enriched Hepatocyte-derived Extracellular Vesicles Promote Capillarization of Liver Sinusoidal Endothelial Cells in Metabolic Dysfunction-associated Steatotic Liver Disease,research_open_access_restricted_reuse,10.1016/j.jcmgh.2025.101721,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce or adapt figures/tables/text,MASLD_LSEC_capillarization_extracellular_vesicle_OGT_HNF1A_Ang2_context,13,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DU_MALAT1_HBV_HCC_ASO_2025,DU_MALAT1_HBV_HCC_ASO_2025,MALAT1 promotes malignancy of HBV-related hepatocellular carcinoma by regulating IGF2BP3-mediated nuclear-cytoplasmic shuttling,research_open_access,10.7150/ijbs.112133,CC BY 4.0; use as evidence/context; original article not redistributed,HBV_HBx_MALAT1_m6A_IGF2BP3_ASO_intervention_context,11,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_PAN_CD133_MASLD_HCC_SIRNA_2025,PAN_CD133_MASLD_HCC_SIRNA_2025,Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma,research_open_access_restricted_commercial_reuse,10.1136/gutjnl-2025-336527,CC BY-NC; use as evidence/context; original article not redistributed,MASLD_HCC_CD133_CSC_VNP_siRNA_multikinase_inhibitor_resistance_context,10,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HUANG_GALNAC_RBC_EV_LIVER_DISEASE_2025,HUANG_GALNAC_RBC_EV_LIVER_DISEASE_2025,Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases,research_open_access_restricted_commercial_reuse,10.2147/IJN.S510937,CC BY-NC; use as evidence/context; original article not redistributed,GalNAc_RBC_EV_hepatocyte_delivery_ASO_siRNA_PJ34_ALF_NAFLD_HCC_context,16,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KARTOUN_MELD_PLUS_CIRRHOSIS_2017,KARTOUN_MELD_PLUS_CIRRHOSIS_2017,The MELD-Plus: A generalizable prediction risk score in cirrhosis,clinical_prediction_model_open_access,10.1371/journal.pone.0186301,CC BY 4.0,clinical_liver_severity_cirrhosis_mortality_risk_score_context,10,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MA_FORMONONETIN_ALDH2_ALD_2025,MA_FORMONONETIN_ALDH2_ALD_2025,Formononetin mitigates alcoholic liver disease by restoring ALDH2 function and inducing ERK1/2–Nrf2 antioxidant signaling,research_article_supporting_liver_context,https://doi.org/10.1016/j.phymed.2025.157408,open_access_CC_BY_NC_ND,supporting_liver_context,3,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_VALLE_HOXB7_HNP_TAMOXIFEN_BREAST_2024,VALLE_HOXB7_HNP_TAMOXIFEN_BREAST_2024,In Vivo HOXB7 Gene Silencing and Cotreatment with Tamoxifen for Luminal A Breast Cancer Therapy,research_article_supporting_siRNA_nanoparticle_safety_context,https://doi.org/10.3390/ph17101325,open_access_CC_BY,supporting_delivery_platform_safety_context,3,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WANG_PMEVL_SEV_SMALL_RNA_PCSK9_2026,WANG_PMEVL_SEV_SMALL_RNA_PCSK9_2026,Robust loading and delivery of functional small RNAs via protein N-myristoylation-induced small extracellular vesicles,research_article_supporting_sEV_small_RNA_delivery_context,https://doi.org/10.1016/j.bioactmat.2026.04.012,open_access_CC_BY,supporting_sEV_RNA_delivery_and_hepatic_safety_context,17,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ANDERSSON_PRECLINICAL_OLIGO_SAFETY_2022,ANDERSSON_PRECLINICAL_OLIGO_SAFETY_2022,Preclinical Safety Assessment of Therapeutic Oligonucleotides,methods_chapter_preclinical_safety_review,10.1007/978-1-0716-2010-6_25,NCBI_Bookshelf_methods_chapter_context_only,direct_preclinical_oligonucleotide_safety_framework,26,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BI_IFNA_DISULFIDPTOSIS_HCC_2026,BI_IFNA_DISULFIDPTOSIS_HCC_2026,Interferon-alpha induces disulfidptosis occurrence in human liver cancer cells,mechanistic_cell_study_liver_cancer,10.3760/cma.j.cn501113-20250612-00233,journal_pdf_user_provided; use as evidence/context only; do not reproduce source figures/tables/text,IFN_alpha_HCC_disulfidptosis_NADPH_Factin_SLC7A11_context,13,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JANAS_GALNAC_RNAI_NONCLINICAL_SAFETY_2018,JANAS_GALNAC_RNAI_NONCLINICAL_SAFETY_2018,The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies,review_platform_nonclinical_safety,10.1177/0192623318792537,SAGE article user_provided; use as evidence/context only; do not reproduce source figures/tables/text,GalNAc_siRNA_ESC_nonclinical_safety_platform_rat_monkey_liver_kidney_RES_context,31,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BOSCO_INCLISIRAN_FH_REALWORLD_2025,BOSCO_INCLISIRAN_FH_REALWORLD_2025,Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience,clinical_real_world_observational_inclisiran,10.1016/j.pcad.2025.05.008,CC BY 4.0,inclisiran_PCSK9_GalNAc_siRNA_real_world_FH_lipid_PWV_ALT_AST_safety_context,23,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DEBACKER_GALNAC_LIVER_DELIVERY_REVIEW_2020,DEBACKER_GALNAC_LIVER_DELIVERY_REVIEW_2020,Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug,review_GalNAc_liver_delivery_clinical_translation,10.1016/j.ymthe.2020.06.015,CC BY 4.0,GalNAc_ASGPR_hepatocyte_delivery_ASO_siRNA_clinical_translation_and_safety_context,28,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RANASINGHE_SIRNA_PHARMACOLOGY_REVIEW_2023,RANASINGHE_SIRNA_PHARMACOLOGY_REVIEW_2023,"Small interfering RNA: Discovery, pharmacology and clinical development — An introductory review",review_siRNA_discovery_pharmacology_clinical_development,10.1111/bph.15972,CC BY open access; user-provided PDF; cite source but do not reproduce full tables/figures/text,siRNA_mechanism_pharmacology_delivery_clinical_landscape_context,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KAMOLA_ASO_HEPATOTOX_SCREEN_2017,KAMOLA_ASO_HEPATOTOX_SCREEN_2017,Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs,peer_reviewed_open_access_article,10.1016/j.omtn.2017.07.003,CC BY-NC-ND 4.0,ASO_gapmer_hepatotoxicity_screening_offtarget_mitigation,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIU_ENDOTHELIAL_AGO1_LNP_ASO_2025,LIU_ENDOTHELIAL_AGO1_LNP_ASO_2025,Endothelial AGO1 Drives Vascular Inflammation and Atherosclerosis via a Non-Canonical Nuclear Mechanism,bioRxiv_preprint_not_peer_reviewed,10.1101/2025.05.01.651783,bioRxiv preprint; author/funder copyright notice says no reuse without permission; use as evidence/context only; do not redistribute source text or figures,LNP_delivered_LNA_gapmer_AGO1_ASO_liver_function_vascular_inflammation_context,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WEISS_GYS1_ASO_POMPE_PREPRINT_2024,WEISS_GYS1_ASO_POMPE_PREPRINT_2024,Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease,bioRxiv_preprint_not_peer_reviewed,10.1101/2024.02.22.580414,bioRxiv preprint; author/funder copyright notice says no reuse without permission; use as evidence/context only; do not redistribute source text or figures,supporting_extrahepatic_ASO_gapmer_safety_and_ALT_AST_monitoring_context,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_OLSON_CHOLANGIOCYTE_CHOLESTASIS_2025,OLSON_CHOLANGIOCYTE_CHOLESTASIS_2025,Dynamic cholangiocyte responses in a murine model of reversible cholestasis: macrophage remodeling and NF-Y-mediated TGFβ1 expression,peer_reviewed_research_article,10.1152/ajpgi.00243.2025,Creative Commons Attribution CC-BY 4.0; use as source evidence/context only; do not redistribute source PDF/figures in generated package,supporting_cholestatic_liver_injury_cholangiocyte_macrophage_fibrosis_context,21,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KANDA_PCDHA11_AMNA_ASO_2024,KANDA_PCDHA11_AMNA_ASO_2024,Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer,peer_reviewed_preclinical_therapeutic_ASO_study,10.1038/s41416-024-02859-5,"Springer Nature exclusive licence; use as source evidence/context only; do not redistribute source PDF, figures, tables, sequences, or long source text",direct_preclinical_AmNA_modified_PCDHA11_ASO_sequence_dependent_reversible_hepatotoxicity_evidence,35,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HJELMGREN_PS_ASO_DDR_2026,HJELMGREN_PS_ASO_DDR_2026,Dysregulation of the DNA damage response by phosphorothioate antisense oligonucleotides,mechanistic_ASO_toxicity_open_access,10.1038/s41467-026-69980-2,Nature Communications open-access article; use as evidence/context only; do not reproduce source figures/tables/text,PS_ASO_DNA_damage_response_phase_separation_toxicity_mechanism,27,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LAN_SIRUBICON_ROS_GALNAC_MASH_2025,LAN_SIRUBICON_ROS_GALNAC_MASH_2025,Dual-targeted siRubicon delivery strategy triggers hepatocellular lipophagy for mitigating liver steatosis,preclinical_liver_siRNA_delivery_open_access,10.1038/s41467-025-61965-x,Nature Communications open-access article; use as evidence/context only; do not reproduce source figures/tables/text,ROS_responsive_GalNAc_hepatocyte_siRNA_delivery_MASH_lipophagy_safety_context,11,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YAMAGUCHI_SCPBNA2_REDUCED_HEPATOTOX_2025,YAMAGUCHI_SCPBNA2_REDUCED_HEPATOTOX_2025,"Cycloalkane Incorporation Into the 2′,4′-Bridge of Locked Nucleic Acid: Enhancing Nuclease Stability, Reducing Phosphorothioate Modifications, and Lowering Hepatotoxicity in Antisense Oligonucleotides",ASO_chemistry_hepatotoxicity_open_access,10.1021/jacsau.5c01005,CC BY 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,scpBNA_scpBNA2_gapmer_ASO_chemistry_reduced_PS_lower_hepatotoxicity,28,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIU_CYP2E1_LNP_APAP_AILI_2025,LIU_CYP2E1_LNP_APAP_AILI_2025,Amelioration of Acetaminophen-Induced Hepatic Oxidative Stress and Inflammation by RNAi Targeting Cyp2e1 In Vivo,preclinical_RNAi_LNP_DILI_open_access,10.3390/cimb47050372,CC BY 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,siCyp2e1_LNP_APAP_acute_liver_injury_ALT_AST_oxidative_stress_inflammation_recovery,17,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KIM_NANP_LIPID_LIVER_TARGETING_2026,KIM_NANP_LIPID_LIVER_TARGETING_2026,Programmable Lipid Functionalization of Nucleic Acid Nanoparticles Modulates Liver Cell-Type Targeting,nucleic_acid_nanoparticle_delivery_open_access,10.1021/acsami.5c24581,CC BY 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,NANP_lipid_functionalization_GalNAc_LDLR_SR-B1_liver_cell_type_targeting_offtarget_uptake,15,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SUN_HCC_RNA_NANOPARTICLE_MULTITARGET_2026,SUN_HCC_RNA_NANOPARTICLE_MULTITARGET_2026,Design of Anti-Tumor RNA Nanoparticles and Their Inhibitory Effect on Hep3B Liver Cancer,RNA_nanoparticle_liver_cancer_open_access,10.3390/biom16010045,CC BY 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,self_assembling_RNA_nanoparticle_Hep3B_hTERT_BIRC5_FGFR1_multitarget_RNAi_safety_context,14,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MEKONNEN_MYC_ASIRNA_DCA_TNBC_2025,MEKONNEN_MYC_ASIRNA_DCA_TNBC_2025,"Design, Screening and Development of Asymmetric siRNAs Targeting the MYC Oncogene in Triple-Negative Breast Cancer",asymmetric_siRNA_design_delivery_safety_open_access_noncommercial,10.4062/biomolther.2024.071,CC BY-NC 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,asymmetric_siRNA_VP_DCA_cholesterol_extrahepatic_delivery_durable_knockdown_safety_context,10,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SOUSA_HDO_MULTIFUNCTIONAL_HELA_2022,SOUSA_HDO_MULTIFUNCTIONAL_HELA_2022,Multi-Functionalized Heteroduplex Antisense Oligonucleotides for Targeted Intracellular Delivery and Gene Silencing in HeLa Cells,HDO_intracellular_delivery_open_access,10.3390/biomedicines10092096,CC BY 4.0; generated variables only; do not reproduce source figures/tables/sequences verbatim,heteroduplex_ASO_multifunctionalization_folate_peptide_delivery_gene_silencing_context,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KUMAGAI_SCPBNA2_PURINE_SYNTHESIS_2025,KUMAGAI_SCPBNA2_PURINE_SYNTHESIS_2025,"Development of Synthetic Routes to 2-O,4-C-Spirocyclopentylene-Bridged Nucleic Acids: Thymidine, Guanosine, and Adenosine",ASO_chemistry_synthesis_open_access,10.1002/chem.202502995,CC BY 4.0; evidence/context only; generated variables only; no source schemes reproduced,scpBNA2_full_monomer_synthesis_T_G_A_chemistry_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BJD_BMP1_SHRNA_AAV_CCL4_FIBROSIS_CONTEXT,BJD_BMP1_SHRNA_AAV_CCL4_FIBROSIS_CONTEXT,Protective effect of knockdown Bmp1 gene on carbon tetrachloride-induced liver fibrosis in mice,shRNA_AAV_liver_fibrosis_context_user_pdf_text_extraction_limited,user_provided_pdf_bjdxxbyxb_57_4_727,user-provided PDF; text extraction limited/garbled; context only until manually reviewed,Bmp1_shRNA_AAV_CCl4_liver_fibrosis_ALT_AST_context_needs_manual_review,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HUANG_AGT_GALNAC_SIRNA_TOXICOLOGY_2025,HUANG_AGT_GALNAC_SIRNA_TOXICOLOGY_2025,"Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen",therapeutic_siRNA_design_pharmacology_toxicology_open_access_restricted_reuse,10.1016/j.omtn.2025.102542,CC BY-NC-ND 4.0; evidence/context only; generated variables only; no source figures/tables/sequences reproduced,complete_GalNAc_siRNA_development_workflow_sequence_screening_modification_pattern_delivery_toxicology_offtarget_PKPD,29,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_QU_CPG_ODN_APAP_TLR9_IRG1_2025,QU_CPG_ODN_APAP_TLR9_IRG1_2025,CpG-oligodeoxynucleotides challenged macrophages ameliorate acetaminophen induced liver injury by activating TLR9/IRG1/itaconate metabolic pathway,CpG_ODN_APAP_liver_injury_open_access,10.1186/s10020-025-01324-0,CC BY 4.0; generated variables only; no source figures/tables/text reproduced,CpG_ODN_TLR9_macrophage_immunomodulation_APAP_liver_injury_IRG1_itaconate_context,11,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_PARK_ERBB2_APTAMER_PET_PK_2023,PARK_ERBB2_APTAMER_PET_PK_2023,In vivo tissue pharmacokinetics of ERBB2-specific binding oligonucleotide-based drugs by PET imaging,aptamer_tissue_PK_PET_open_access_noncommercial,10.1111/cts.13522,CC BY-NC 4.0; generated variables only; no source figures/tables reproduced,oligonucleotide_aptamer_PET_tissue_PK_biodistribution_target_specificity_excretion_context,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_XI_HCC_CHROMATIN_DGAT1_SIRNA_2025,XI_HCC_CHROMATIN_DGAT1_SIRNA_2025,Chromatin accessibility module identified by single-cell sequencing underlies the diagnosis and prognosis of hepatocellular carcinoma,single_cell_HCC_epigenomics_siRNA_validation_open_access,10.4254/wjh.v17.i6.107329,open access; evidence/context only; generated variables only if later promoted,HCC_chromatin_accessibility_DGAT1_siRNA_functional_validation_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LI_AIH_CERNA_NETWORK_2022,LI_AIH_CERNA_NETWORK_2022,Construction and function analysis of the LncRNA-miRNA-mRNA competing endogenous RNA network in autoimmune hepatitis,autoimmune_hepatitis_ceRNA_network_open_access,10.1186/s12920-022-01416-4,CC BY 4.0; evidence/context only; generated variables only if later promoted,autoimmune_hepatitis_lncRNA_miRNA_mRNA_network_ALT_AST_MDA_NO_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_TERADA_BROTHERS_ASO_PNA_TOEHOLD_2023,TERADA_BROTHERS_ASO_PNA_TOEHOLD_2023,Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry,direct_ASO_hepatotoxicity_mitigation_mechanism_open_access,10.1038/s41467-023-43714-0,open access; generated variables only; no source figures/tables/sequences reproduced,BROTHERS_ASO_PNA_toehold_duplex_reduces_protein_binding_RNA_offtarget_and_ALT_hepatotoxicity,18,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_PRAKASH_APOC3_LONG_ACTING_GALNAC_SIRNA_2025,PRAKASH_APOC3_LONG_ACTING_GALNAC_SIRNA_2025,Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia,direct_GalNAc_siRNA_SAR_duration_tolerability_open_access_noncommercial,10.1093/nar/gkaf1063,CC BY-NC; generated variables only; no source figures/tables/sequences reproduced,APOC3_GalNAc_siRNA_chemical_scaffold_SAR_potency_duration_selectivity_tolerability_rodent_NHP,18,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KIM_GALNAC_SIRNA_LCMS_DPPT_2025,KIM_GALNAC_SIRNA_LCMS_DPPT_2025,Differential Protein Precipitation-Based GalNAc-siRNA Sample Preparation with LC/MS Method Development Workflow in Plasma,GalNAc_siRNA_bioanalysis_LCMS_method_open_access_restricted_reuse,10.1021/acs.analchem.5c01587,CC BY-NC-ND 4.0; generated variables only; no source figures/tables reproduced,GalNAc_siRNA_quantification_DPPT_LCMS_PK_TK_bioanalysis_reproducibility_context,4,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_UMEZU_ORAL_MIR29A_LIVER_FIBROSIS_NA_2025,UMEZU_ORAL_MIR29A_LIVER_FIBROSIS_NA_2025,Development of novel nucleic acid therapy aimed at directly controlling liver fibrosis,modified_miRNA_like_liver_fibrosis_therapy_open_access_restricted_reuse,10.1016/j.omtn.2024.102438,CC BY-NC-ND 4.0; generated variables only; no source figures/tables/sequences reproduced,oral_nuclease_resistant_miR29a_like_RNA_DNA_hybrid_LNA_PS_liver_fibrosis_COL1A1_PDGFC,8,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LU_GT_MULTI_SIRNA_HCC_2025,LU_GT_MULTI_SIRNA_HCC_2025,Development of a Dual Gene-Targeted Multi-Sirna with Branched Structure and Its Role in the Therapy of Liver Cancer,branched_multi_siRNA_HCC_open_access,10.3390/ph18121844,CC BY 4.0; evidence/context only; generated variables only if later promoted,dual_gene_branched_multi_siRNA_HCC_GP73_hTERT_biosafety_context,3,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JIANG_LNP_CRISPR_HAO1_PH1_2025,JIANG_LNP_CRISPR_HAO1_PH1_2025,Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption,liver_targeted_LNP_CRISPR_Cas9_long_term_safety_open_access_restricted_text_mining,10.1016/j.ymthe.2024.10.003,open access but publisher reserves text/data mining and AI training rights; generated variables only; no source figures/tables/sequences reproduced,LNP_Cas9_mRNA_sgRNA_liver_delivery_HAO1_Hao1_PH1_urinary_oxalate_offtarget_liver_toxicity_immune_response_long_term,7,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_GOTFRID_PS_LNA_HIV_ASO_ACTIVITY_2026,GOTFRID_PS_LNA_HIV_ASO_ACTIVITY_2026,Investigation of the activity of phosphothioate and phosphothioate-LNA-modified oligonucleotides against HIV-1,PS_and_PS_LNA_ASO_activity_internalization_toxicity_open_access,10.3389/fmed.2026.1719202,CC BY; generated variables only; no source figures/tables/sequences reproduced,PS_ASO_vs_PS_LNA_ASO_internalization_cytotoxicity_antiviral_activity_cellular_uptake_vehicle_free_context,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_XU_FGF21_MAPK1_DAIRY_KETOSIS_SIRNA_2025,XU_FGF21_MAPK1_DAIRY_KETOSIS_SIRNA_2025,FGF21-MAPK1 Imbalance Disrupts Hepatic Lipid Metabolism in Dairy Cow Ketosis,bovine_liver_lipid_metabolism_siRNA_functional_context,10.3390/life15091339,CC BY 4.0; evidence/context only; generated variables only if later promoted,BHB_bovine_hepatocyte_MAPK1_siRNA_lipid_metabolism_FGF21_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ELGHAZZI_GENE_SILENCING_GI_GU_TUMORS_REVIEW_2025,ELGHAZZI_GENE_SILENCING_GI_GU_TUMORS_REVIEW_2025,"Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors",review_gene_silencing_oncology_context,10.3389/fimmu.2025.1657040,CC BY; review context only,ASO_siRNA_miRNA_mechanisms_delivery_modifications_clinical_oncology_review_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YANG_PIRNA_CANCER_DIAGNOSTIC_THERAPEUTIC_REVIEW_2026,YANG_PIRNA_CANCER_DIAGNOSTIC_THERAPEUTIC_REVIEW_2026,Emerging roles of PIWI-interacting RNAs in cancer molecular diagnostics and therapeutics,review_piRNA_cancer_context,10.3389/fmolb.2026.1775335,CC BY; review context only,piRNA_PIWI_cancer_diagnostics_therapeutics_review_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SCHLEGEL_ESCPLUS_SEED_PAIRING_GALNAC_SIRNA_2022,SCHLEGEL_ESCPLUS_SEED_PAIRING_GALNAC_SIRNA_2022,From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization,direct_GalNAc_siRNA_offtarget_hepatotoxicity_mitigation_primary_mechanistic_translation,10.1093/nar/gkac539,CC BY-NC; generated variables only; no source figures/tables/sequences reproduced,GalNAc_siRNA_ESCplus_GNA_2_5_RNA_seed_pairing_destabilization_RNAi_offtarget_hepatotoxicity_ALT_ALN_HBV_VIR2218,8,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DHARA_LNA_PHOSPHOTHIOTRIESTER_SSO_CLICK_2025,DHARA_LNA_PHOSPHOTHIOTRIESTER_SSO_CLICK_2025,Biophysical and biological properties of splice-switching oligonucleotides and click conjugates containing LNA-phosphothiotriester linkages,modified_oligonucleotide_backbone_biophysical_splice_switching_primary_chemistry,10.1093/nar/gkaf1263,CC BY 4.0; generated variables only; no source figures/tables/sequences reproduced,LNA_phosphothiotriester_charge_neutral_backbone_click_conjugates_duplex_stability_gymnosis_splice_switching_bioactivity,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LI_FXR_JNK_G0S2_TRIPTOLIDE_HEPATOTOXICITY_2025,LI_FXR_JNK_G0S2_TRIPTOLIDE_HEPATOTOXICITY_2025,FXR as a pivotal role linking JNK and G0s2 mitigates triptolide-induced hepatotoxicity through the regulation of metabolic disorder of liver,drug_induced_liver_injury_metabolic_pathway_siRNA_mechanism_primary,10.1016/j.phrs.2025.107738,CC BY 4.0; generated variables only; no source figures/tables/text reproduced,triptolide_DILI_ALT_AST_JNK_FXR_G0s2_bile_acids_lipids_carnitine_siRNA_in_vitro_metabolic_hepatotoxicity_context,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JEON_COP1_HCC_LIPID_STEMNESS_SIRNA_2026,JEON_COP1_HCC_LIPID_STEMNESS_SIRNA_2026,Functional Role of COP1 Gene in Hepatocellular Carcinoma Lipid Metabolism and Stemness,HCC_siRNA_lipid_metabolism_context,10.1111/gtc.70108,CC BY 4.0; context only unless later promoted,COP1_siRNA_HCC_lipid_metabolism_stemness_AKR1D1_TMEM65_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SCHLEGEL_GKAC539_DUPLICATE_UPLOAD_2022,SCHLEGEL_GKAC539_DUPLICATE_UPLOAD_2022,Duplicate upload of From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization,duplicate_upload_not_integrated_separately,10.1093/nar/gkac539,duplicate of source SCHLEGEL_ESCPLUS_SEED_PAIRING_GALNAC_SIRNA_2022,duplicate_upload_skipped,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BUREL_GAPMER_RNASEH1_LONG_PREMRNA_HEPATOTOX_2016,BUREL_GAPMER_RNASEH1_LONG_PREMRNA_HEPATOTOX_2016,Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts,direct_ASO_gapmer_hepatotoxicity_mechanism_primary_transcriptomics,10.1093/nar/gkv1210,CC BY 4.0; generated variables only; no source figures/tables/sequences reproduced,high_affinity_gapmer_LNA_cEt_RNaseH1_promiscuous_offtarget_very_long_pre_mRNA_ALT_AST_hepatotoxicity_mechanism,9,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JIANG_AOC_FREE_ASO_PAYLOAD_HYBRIDIZATION_LCMS_2024,JIANG_AOC_FREE_ASO_PAYLOAD_HYBRIDIZATION_LCMS_2024,Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS,ASO_bioanalysis_PK_PD_measurement_primary_method,10.1080/17576180.2024.2368339,CC BY-NC-ND 4.0; generated variables only; no source figures/tables/text reproduced,free_ASO_payload_AOC_Fab_ASO_hybridization_LCMS_tissue_PK_biodistribution_parent_linker_interference_methodology,5,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WAN_PUM1_EXOSOMES_MASLD_HSC_FIBROSIS_2025,WAN_PUM1_EXOSOMES_MASLD_HSC_FIBROSIS_2025,Hepatocyte-derived Pumilio1-enriched exosomes inhibit HSC activation by suppressing tropomyosin-4 translation,MASLD_liver_fibrosis_exosome_RNA_binding_shRNA_siRNA_primary,10.1097/HC9.0000000000000759,CC BY 4.0; generated variables only; no source figures/tables/text reproduced,PUM1_hepatocyte_exosome_MASLD_lipotoxic_death_HSC_activation_TPM4_translation_AAV8_shRNA_siRNA_context,3,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZHU_HMMR_HCC_4MU_SIRNA_2026,ZHU_HMMR_HCC_4MU_SIRNA_2026,HMMR inhibition by 4-methylumbelliferone is effective in preclinical hepatocellular carcinoma models,HCC_target_validation_siRNA_context,10.14670/HH-18-937,CC BY 4.0; context only unless later promoted,HMMR_siRNA_HCC_drug_resistant_cell_proliferation_migration_4MU_context,1,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_GHOLIKHANI_APTAMER_BREAST_CANCER_REVIEW_2022,GHOLIKHANI_APTAMER_BREAST_CANCER_REVIEW_2022,"Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics",aptamer_review_context_only,10.3390/ijms232214475,CC BY 4.0; review context only unless later promoted,aptamer_delivery_diagnostics_therapeutics_review_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JOSHI_BEPIROVIRSEN_B_TOGETHER_IMMUNOMODULATION_2026,JOSHI_BEPIROVIRSEN_B_TOGETHER_IMMUNOMODULATION_2026,Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study),clinical_biomarker_original_article,10.1007/s12072-025-10917-0,open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_ASO_clinical_ALT_immunomodulation_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_TSUBOI_SNA_ASO_SGLT2_KIDNEY_SYSTEMIC_SAFETY_2025,TSUBOI_SNA_ASO_SGLT2_KIDNEY_SYSTEMIC_SAFETY_2025,In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney,preclinical_original_article,10.1016/j.omtn.2024.102387,open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_ASO_chemistry_delivery_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KANNAN_POLYAMINE_PLNP_RNA_DELIVERY_SAFETY_2025,KANNAN_POLYAMINE_PLNP_RNA_DELIVERY_SAFETY_2025,Incorporation of a polyamine into lipid nanoparticles increases the endosomal release and transfection of nucleic acids without toxicity,delivery_platform_original_article,10.1016/j.jconrel.2025.114366,CC BY-NC open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_LNP_RNA_delivery_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_TAKENOYA_GALP_HFD_LIVER_TRANSCRIPTOME_METABOLOME_2023,TAKENOYA_GALP_HFD_LIVER_TRANSCRIPTOME_METABOLOME_2023,Transcriptomic and metabolome analyses of liver in high-fat diet mice after intranasal GALP,liver_omics_original_article,10.3390/ijms242115825,CC BY open-access article; deferred from core generation,deferred_liver_metabolism_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SHEVELEV_SIRNA_THERAPEUTICS_REVIEW_2025,SHEVELEV_SIRNA_THERAPEUTICS_REVIEW_2025,siRNA therapeutics for the treatment of hereditary diseases and other conditions: A review,review,10.3390/ijms26178651,CC BY open-access review; deferred from core generation,deferred_review_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_VAN_LEEUWEN_ASO_MULTIOMICS_TIME_RESOLVED_SAFETY_2026,VAN_LEEUWEN_ASO_MULTIOMICS_TIME_RESOLVED_SAFETY_2026,Integrating transcriptomics and proteomics to assess antisense oligonucleotide safety and efficacy: a time-resolved approach,ASO_multiomics_original_article,10.1093/narmme/ugag016,CC BY-NC open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_ASO_safety_transcriptomics_proteomics_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RIDER_SLN360_LPA_GALNAC_SIRNA_PRECLINICAL_TOX_2022,RIDER_SLN360_LPA_GALNAC_SIRNA_PRECLINICAL_TOX_2022,"Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein(a) in Cardiovascular Disease",preclinical_toxicology_original_article,10.1093/toxsci/kfac067,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_GalNAc_siRNA_preclinical_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MA_KUPFFER_BIOMIMETIC_ZIF8_BRCC3_SIRNA_SRLI_2025,MA_KUPFFER_BIOMIMETIC_ZIF8_BRCC3_SIRNA_SRLI_2025,Kupffer cells biomimetic nanoparticles alleviate sepsis related liver injury,nanomedicine_siRNA_original_article,10.1186/s12951-025-03860-7,CC BY-NC-ND open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_siRNA_liver_injury_nanoparticle_delivery_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LI_PKHD1_ARPKD_ASO_SPLICE_RESCUE_2023,LI_PKHD1_ARPKD_ASO_SPLICE_RESCUE_2023,A Potential Therapy Using Antisense Oligonucleotides to Treat Autosomal Recessive Polycystic Kidney Disease,ASO_splicing_original_article_deferred,10.3390/jcm12041428,CC BY open-access article; deferred from core generation,deferred_ASO_splicing_rare_disease_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JIA_ATP7B_WILSON_MICROARRAY_DIAGNOSTIC_2022,JIA_ATP7B_WILSON_MICROARRAY_DIAGNOSTIC_2022,Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China,diagnostic_microarray_original_article_deferred,10.1002/jcla.24735,CC BY-NC-ND open-access article; deferred from core generation,deferred_liver_genetic_diagnostics_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BAI_EZH2_EXON_SKIPPING_HCC_ASO_2025,BAI_EZH2_EXON_SKIPPING_HCC_ASO_2025,Antisense-mediated exon skipping targeting EZH2 suppresses tumor growth in a xenograft mouse model of hepatocellular carcinoma,splice_switching_ASO_liver_cancer_original_article,10.1016/j.ymthe.2025.02.032,publisher article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_liver_ASO_splice_switching_efficacy_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KABURAGI_TOC_HDO_DRG_SCIATIC_SYSTEMIC_DELIVERY_2022,KABURAGI_TOC_HDO_DRG_SCIATIC_SYSTEMIC_DELIVERY_2022,Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve,HDO_ASO_delivery_original_article,10.1016/j.omtn.2022.05.006,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_extrahepatic_ASO_HDO_delivery_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DAI_XIST_MIR663A_GPX4_HSC_FERROPTOSIS_FIBROSIS_2026,DAI_XIST_MIR663A_GPX4_HSC_FERROPTOSIS_FIBROSIS_2026,Long noncoding RNA X-inactive-specific transcript promotes hepatic fibrosis by suppressing ferroptosis in hepatic stellate cells via the miR-663a/GPX4 axis,lncRNA_siRNA_shRNA_liver_fibrosis_original_article,10.3389/fphys.2025.1734886,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_RNA_perturbation_HSC_ferroptosis_fibrosis_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YUAN_LIVTAC_GALNAC_PROTAC_BRD4_FIBROSIS_2025,YUAN_LIVTAC_GALNAC_PROTAC_BRD4_FIBROSIS_2025,Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models,liver_targeted_GalNAc_PROTAC_original_article_deferred,10.7150/thno.113852,CC BY open-access article; deferred from core oligo generation,deferred_GalNAc_non_oligo_liver_targeting_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_CAI_LYCIUM_POLYSACCHARIDES_ETHANOL_LIVER_INJURY_2025,CAI_LYCIUM_POLYSACCHARIDES_ETHANOL_LIVER_INJURY_2025,Lycium barbarum Polysaccharides Alleviate Ethanol-Induced Liver Injury by Activating PPAR-alpha and Inhibiting NLRP-3/Caspase-1-Mediated Pyroptosis,hepatoprotection_original_article_deferred,10.1002/fsn3.70172,CC BY open-access article; deferred from core generation,deferred_non_oligo_hepatoprotection_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIN_GALNAC_SICIDEB_MASH_STEATOSIS_FIBROSIS_2025,LIN_GALNAC_SICIDEB_MASH_STEATOSIS_FIBROSIS_2025,Targeting CIDEB alleviates liver steatosis and fibrosis in mouse MASH models,GalNAc_siRNA_MASH_original_article,10.1016/j.omtn.2025.102567,CC BY-NC-ND open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_liver_GalNAc_siRNA_MASH_safety_efficacy_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KURODA_ASO_LATE_ONSET_NEUROTOX_5CP_MODIFICATIONS_2025,KURODA_ASO_LATE_ONSET_NEUROTOX_5CP_MODIFICATIONS_2025,Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications,ASO_CNS_toxicity_chemical_modification_original_article,10.1016/j.omtn.2025.102692,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_ASO_toxicity_mitigation_chemistry_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KHORSANDI_GALNAC_SICEBPB_MASLD_HOMEOSTASIS_2026,KHORSANDI_GALNAC_SICEBPB_MASLD_HOMEOSTASIS_2026,GalNAc-conjugated siRNA targeting C/EBPbeta reverses metabolic dysfunction and restores liver homeostasis in a murine MASLD model,GalNAc_siRNA_MASLD_original_article,10.1016/j.omtn.2026.102865,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,direct_liver_GalNAc_siRNA_MASLD_safety_homeostasis_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WANG_TRIVALENT_DISULFIDE_MASKED_ODN_DELIVERY_2024,WANG_TRIVALENT_DISULFIDE_MASKED_ODN_DELIVERY_2024,Trivalent Disulfide Unit-Masked System Efficiently Delivers Large Oligonucleotide,oligonucleotide_delivery_chemistry_original_article,10.3390/molecules29174223,CC BY open-access article; use as evidence/context only; do not reproduce source figures/tables/text,supporting_oligonucleotide_delivery_chemistry_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_NASTASE_NSCLC_LONG_TERM_SURVIVAL_MARKERS_2022,NASTASE_NSCLC_LONG_TERM_SURVIVAL_MARKERS_2022,Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients,cancer_genomics_microarray_WES_article_deferred,10.21873/cgp.20306,freely accessible article; deferred from oligo toxicity generator,deferred_non_oligo_NSCLC_genomics_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZHANG_MPTP_OXMTDNA_MASH_ITPR3_NLRP3_2025,ZHANG_MPTP_OXMTDNA_MASH_ITPR3_NLRP3_2025,MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via ITPR3/Ca2+/NLRP3 pathway,primary_research_open_access,10.1186/s12967-025-07302-8,CC BY-NC-ND 4.0; use as evidence/context only; do not reproduce/adapt source figures/tables/text,supporting_liver_injury_pyroptosis_mechanism,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YANG_NG2_CSPG4_SIRNA_LIVER_FIBROSIS_2023,YANG_NG2_CSPG4_SIRNA_LIVER_FIBROSIS_2023,Neuron-Glial Antigen 2 participates in liver fibrosis via regulating BMSC differentiation to myofibroblast,primary_research_open_access,10.3390/ijms24021177,CC BY 4.0; use as evidence/context only; do not reproduce source figures/tables/text,direct_siRNA_liver_fibrosis_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HUAYAMARES_HNSCC_LNP_TUMOR_TROPISM_LIVER_DETARGET_2023,HUAYAMARES_HNSCC_LNP_TUMOR_TROPISM_LIVER_DETARGET_2023,High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo,primary_research_manuscript,10.1016/j.jconrel.2023.04.005,publisher manuscript; use as evidence/context only; do not reproduce source figures/tables/text,supporting_LNP_biodistribution_liver_detargeting_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_HUANG_NANOPARTICLE_SIRNA_ONCOLOGY_REVIEW_2022,HUANG_NANOPARTICLE_SIRNA_ONCOLOGY_REVIEW_2022,Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic siRNA in Precision Oncology,review_open_access,10.3390/pharmaceutics14081586,"CC BY 4.0; review-only; use for narrative/context, not core generated table",deferred_review_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RUCHI_EVOLUTION_ASO_CHEMISTRY_DELIVERY_REVIEW_2025,RUCHI_EVOLUTION_ASO_CHEMISTRY_DELIVERY_REVIEW_2025,Evolution of Antisense Oligonucleotides: Navigating Nucleic Acid Chemistry and Delivery Challenges,review_author_manuscript,10.1080/17460441.2024.2440095,"author manuscript/review; use for narrative/context, not core generated table",deferred_review_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SINHA_NNMT_ASO_MACROPHAGE_ATHEROSCLEROSIS_2025,SINHA_NNMT_ASO_MACROPHAGE_ATHEROSCLEROSIS_2025,NAD metabolism regulates proliferation of macrophages in atherosclerosis,ASO_siRNA_immunometabolism_original_article,10.1161/ATVBAHA.125.323185,author manuscript/open access via PMC; use as evidence/context only,supporting_systemic_ASO_macrophage_immunometabolism_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YAMAGUCHI_TY1_ORAL_NCRNA_MACROPHAGE_C2_2025,YAMAGUCHI_TY1_ORAL_NCRNA_MACROPHAGE_C2_2025,"Oral Bioavailability of a Noncoding RNA Drug, TY1, That Acts on Macrophages",oral_ncRNA_delivery_original_article,10.1002/jex2.70081,CC BY open-access article; use as evidence/context only,supporting_oral_macrophage_active_ncRNA_delivery_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YU_DUAL_RGD_DSRBD_18HIS_TUMOR_SIRNA_DELIVERY_2021,YU_DUAL_RGD_DSRBD_18HIS_TUMOR_SIRNA_DELIVERY_2021,Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery,siRNA_delivery_nanocarrier_original_article,10.3390/pharmaceutics13122182,CC BY open-access article; use as evidence/context only,supporting_extrahepatic_tumor_targeted_siRNA_delivery_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LARIJANI_P21_SHRNA_CARTILAGE_REPAIR_2026,LARIJANI_P21_SHRNA_CARTILAGE_REPAIR_2026,p21 Knockdown as a Therapeutic Strategy for Focal Cartilage Injury Repair,lentiviral_shRNA_cartilage_original_article_deferred,10.1096/fj.202600387RRR,CC BY open-access article; deferred,deferred_lentiviral_shRNA_cartilage_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_THONGSRI_PANDURATIN_A_HBV_HNF1A_2026,THONGSRI_PANDURATIN_A_HBV_HNF1A_2026,Panduratin A suppresses hepatitis B virus by targeting HNF1alpha,small_molecule_HBV_liver_model_article_deferred,10.1186/s13020-025-01285-w,CC BY open-access article; deferred,deferred_non_oligo_HBV_small_molecule_liver_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RING_PIKFYVE_APILIMOD_HEV_ENTRY_2026,RING_PIKFYVE_APILIMOD_HEV_ENTRY_2026,Phosphoinositide kinase PIKfyve inhibitor apilimod blocks hepatitis E virus infection,host_directed_HEV_antiviral_original_article_deferred,10.1136/egastro-2025-100348,CC BY-NC; no commercial reuse; deferred context-only source,deferred_non_oligo_host_directed_hepatocyte_antiviral_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SADDIQUE_RNAI_CARDIAC_FAILURE_SYSTEMATIC_REVIEW_2024,SADDIQUE_RNAI_CARDIAC_FAILURE_SYSTEMATIC_REVIEW_2024,Safety and effectiveness of interference RNA based therapeutics in cardiac failure: A systematic review,RNAi_cardiac_failure_systematic_review_deferred,10.1016/j.hrtlng.2024.08.015,CC BY 4.0; review-only deferred context source,deferred_review_only_cardiac_RNAi_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_RAMESH_KUMAR_RPSAP52_LNA_GAPMER_OVARIAN_PDOX_2025,RAMESH_KUMAR_RPSAP52_LNA_GAPMER_OVARIAN_PDOX_2025,Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models,LNA_GapmeR_lncRNA_pseudogene_original_article,10.1016/j.ejca.2025.116040,CC BY-NC; source used as scientific context/provenance only,supporting_gapmer_ASO_extrahepatic_oncology_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KOSTYUSHEVA_BIOLOGICS_HYB_TARGETED_RNA_DELIVERY_2025,KOSTYUSHEVA_BIOLOGICS_HYB_TARGETED_RNA_DELIVERY_2025,Biologics-based technologies for highly efficient and targeted RNA delivery,biologics_based_RNA_delivery_original_article,10.1016/j.ymthe.2024.11.004,Elsevier/Molecular Therapy article; source used as scientific context/provenance only; do not redistribute source figures/tables/text,supporting_EMNV_liposome_hybrid_siRNA_delivery_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BHATIA_PELACARSEN_LPA_ASO_REVIEW_2025,BHATIA_PELACARSEN_LPA_ASO_REVIEW_2025,Pelacarsen: Mechanism of action and Lp(a)-lowering effect,clinical_ASO_review_deferred,10.1016/j.jacl.2025.06.004,CC BY-NC-ND; review-only deferred context source,deferred_review_only_pelacarsen_clinical_ASO_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BARON_ALPHA_GAG_MS2_CRISPR_RNA_DELIVERY_2022,BARON_ALPHA_GAG_MS2_CRISPR_RNA_DELIVERY_2022,Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells,CRISPR_RNA_delivery_original_article_deferred,10.1016/j.omtn.2021.12.033,CC BY; deferred source used as context only,deferred_gene_editing_vector_delivery_context_only,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MADILL_HALLORAN_MMDX_TRANSPLANT_DIAGNOSTICS_2024,MADILL_HALLORAN_MMDX_TRANSPLANT_DIAGNOSTICS_2024,Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the Molecular Microscope Diagnostic System,transplant_molecular_diagnostics_review_deferred,10.1042/CS20220530,CC BY; deferred source used as context only,deferred_diagnostics_and_machine_learning_context_only,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_STEEL_CD81_GALNAC_SIRNA_MALARIA_PROTECTION_2025,STEEL_CD81_GALNAC_SIRNA_MALARIA_PROTECTION_2025,Protection from malaria infection using liver-targeted siRNA,GalNAc_siRNA_liver_prophylaxis_original_article,10.1016/j.omtm.2025.101516,CC BY; generated variables only; do not reproduce source figures/tables/text,direct_liver_targeted_GalNAc_siRNA_hepatocyte_knockdown_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LI_RBM39_HEPATOCYTE_IFN_INNATE_IMMUNITY_2025,LI_RBM39_HEPATOCYTE_IFN_INNATE_IMMUNITY_2025,RBM39 shapes innate immunity by controlling the expression of key factors of the interferon response,hepatocyte_innate_immunity_original_article,10.3389/fimmu.2025.1568056,CC BY; generated variables only; do not reproduce source figures/tables/text,supporting_hepatocyte_interferon_and_oligo_immune_activation_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_DMITRIEV_GALNAC_SIRNA_PCSK9_LIQUID_PHASE_2026,DMITRIEV_GALNAC_SIRNA_PCSK9_LIQUID_PHASE_2026,Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates: Comparative Efficiency Validation in PCSK9 Targeting,GalNAc_siRNA_design_synthesis_original_article,10.3390/molecules31030476,CC BY; generated variables only; do not reproduce source figures/tables/text,direct_GalNAc_siRNA_design_synthesis_and_PCSK9_validation_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KIM_LARP6_HSC_FIBROSIS_DSI_RNA_2026,KIM_LARP6_HSC_FIBROSIS_DSI_RNA_2026,RNA-binding protein LARP6 coordinates hepatic stellate cell activation and liver fibrosis,human_liver_fibrosis_dsiRNA_original_article,10.1172/JCI197923,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,direct_HSC_fibrosis_dsiRNA_and_human_MASH_MetALD_spheroid_module,26,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SUBRAMANIAN_RNAI_RHEOSTAT_AAV_TRANSGENE_2023,SUBRAMANIAN_RNAI_RHEOSTAT_AAV_TRANSGENE_2023,RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes,RNAi_transgene_control_original_article,10.1038/s41467-023-37774-5,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_GalNAc_siRNA_REVERSIR_AAV_expression_control_module,10,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_FRIEDRICH_AIGNER_THERAPEUTIC_SIRNA_REVIEW_2022,FRIEDRICH_AIGNER_THERAPEUTIC_SIRNA_REVIEW_2022,Therapeutic siRNA: State-of-the-Art and Future Perspectives,siRNA_review_deferred,10.1007/s40259-022-00549-3,CC BY 4.0; deferred source used as context only,deferred_background_review_only,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_JANAS_GALNAC_SIRNA_OFFTARGET_RAT_HEPATOTOX_2018,JANAS_GALNAC_SIRNA_OFFTARGET_RAT_HEPATOTOX_2018,Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity,GalNAc_siRNA_hepatotoxicity_mechanism_original_article,10.1038/s41467-018-02989-4,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,direct_seed_offtarget_rat_hepatotoxicity_module,29,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_BERGEN_DILIMAP_TOXPREDICTOR_DILI_2025,BERGEN_DILIMAP_TOXPREDICTOR_DILI_2025,A large-scale human toxicogenomics resource for drug-induced liver injury prediction,DILI_toxicogenomics_original_article_supporting,10.1038/s41467-025-65690-3,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_human_hepatocyte_DILI_modeling_and_validation_module,15,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_GERETTI_RO7239958_GALNAC_LNA_ASO_HBV_PHASE1_2025,GERETTI_RO7239958_GALNAC_LNA_ASO_HBV_PHASE1_2025,"Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection",clinical_GalNAc_LNA_ASO_phase1_original_article,10.1128/aac.00679-25,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,direct_clinical_LNA_ASO_PK_PD_safety_window_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIU_HYDROGEN_HNP_TGFB1_SIRNA_PULMONARY_FIBROSIS_2025,LIU_HYDROGEN_HNP_TGFB1_SIRNA_PULMONARY_FIBROSIS_2025,Hydrogen-induced disruption of the airway mucus barrier enhances nebulized RNA delivery to reverse pulmonary fibrosis,inhaled_siRNA_delivery_original_article,10.1126/sciadv.adt2752,CC BY-NC 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_extrahepatic_nebulized_siRNA_delivery_and_macrophage_safety_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SUN_PCSK9_SIRNA_STING_CANCER_IMMUNOTHERAPY_2025,SUN_PCSK9_SIRNA_STING_CANCER_IMMUNOTHERAPY_2025,Silencing PCSK9 reshapes the spatiotemporal activation of STING for safe and effective cancer immunotherapy,PCSK9_siRNA_STING_immunotherapy_original_article,10.1038/s41467-025-66630-x,standard/open access metadata; generated variables only; do not reproduce source figures/tables/text,supporting_siRNA_STING_hepatic_immune_toxicity_modulation_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_XIE_TOP2A_HCC_SCRNA_SIRNA_KNOCKDOWN_2025,XIE_TOP2A_HCC_SCRNA_SIRNA_KNOCKDOWN_2025,Single cell-RNA sequencing reveal TOP2A as a key driver of hepatocellular carcinoma progression,HCC_siRNA_knockdown_biology_deferred,10.1038/s41598-025-16785-w,open access; deferred source used as context only,deferred_HCC_target_validation_context_only,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WEISS_GYS1_ASO_POMPE_SKELETAL_MUSCLE_2025,WEISS_GYS1_ASO_POMPE_SKELETAL_MUSCLE_2025,Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease,ASO_skeletal_muscle_original_article,10.1002/ctm2.70314,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_extrahepatic_ASO_tissue_safety_and_substrate_reduction_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_YU_SPTLC2_LNP_SIRNA_MASH_CERAMIDE_2025,YU_SPTLC2_LNP_SIRNA_MASH_CERAMIDE_2025,Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH,LNP_siRNA_MASH_original_article,10.1126/sciadv.adx2681,CC BY-NC 4.0; generated variables only; do not reproduce source figures/tables/text,direct_hepatocyte_LNP_siRNA_MASH_ceramide_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZENG_PDL1_APTAMER_CD47_SIRNA_TREG_HCC_2025,ZENG_PDL1_APTAMER_CD47_SIRNA_TREG_HCC_2025,Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera,aptamer_siRNA_chimera_HCC_immunotherapy_original_article,10.1186/s43556-025-00392-2,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_cell_selective_aptamer_siRNA_immune_oncology_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_WANG_THBS1_RILI_PROTEOMICS_SIRNA_2025,WANG_THBS1_RILI_PROTEOMICS_SIRNA_2025,THBS1 as a candidate biomarker and fibrotic mediator in radiation-induced liver injury,radiation_induced_liver_injury_proteomics_siRNA_original_article,10.3389/fphar.2025.1659870,CC BY 4.0; generated variables only; do not reproduce source figures/tables/text,supporting_liver_injury_biomarker_and_fibrosis_mechanism_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LIU_NEDD4_NEFA_KETOTIC_COW_LIVER_2026,LIU_NEDD4_NEFA_KETOTIC_COW_LIVER_2026,The E3 ubiquitin ligase NEDD4 protects against nonesterified fatty acid-induced hepatic inflammatory injury in ketotic cows,bovine_ketosis_liver_injury_siRNA_mechanistic_deferred,10.3168/jds.2025-27574,CC BY 4.0; deferred source used as context only,deferred_non_therapeutic_siRNA_bovine_ketosis_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_CHEN_HNF4A_KETOTIC_COW_HEPATOCYTE_SIRNA_2025,CHEN_HNF4A_KETOTIC_COW_HEPATOCYTE_SIRNA_2025,The hepatic expression status of hepatocyte nuclear factor 4alpha in subclinical and clinical ketotic dairy cows and its impact on lipid metabolism in hepatocytes,bovine_ketosis_hepatocyte_siRNA_mechanistic_deferred,10.3168/jds.2025-26548,CC BY 4.0; deferred source used as context only,deferred_non_therapeutic_siRNA_bovine_ketosis_lipid_metabolism_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_TATSUKAWA_TG_KERATIN_BILE_ACID_HEPATOCYTE_DEATH_2025,TATSUKAWA_TG_KERATIN_BILE_ACID_HEPATOCYTE_DEATH_2025,Transglutaminase-mediated cytokeratin modifications implicated in bile-acid-induced hepatocyte death,cholestatic_liver_injury_original_article,10.1111/febs.70281,CC BY-NC; generated variables only; do not reproduce source figures/tables/text,supporting_bile_acid_hepatocyte_death_and_fibrosis_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZHANG_TRIM16_YAP1_NRF2_SEPTIC_LIVER_INJURY_2026,ZHANG_TRIM16_YAP1_NRF2_SEPTIC_LIVER_INJURY_2026,TRIM16 mediates YAP1 K63-linked ubiquitination to alleviate sepsis-induced acute liver injury through YAP/Nrf2 axis in mice,septic_liver_injury_original_article,10.1186/s13578-025-01517-4,CC BY-NC-ND; generated variables only; do not reproduce source figures/tables/text,supporting_inflammation_oxidative_stress_liver_injury_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ZHOU_TDEV_MEMBRANE_LEV_SIRNA_HCC_DELIVERY_2022,ZHOU_TDEV_MEMBRANE_LEV_SIRNA_HCC_DELIVERY_2022,Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation,advanced_siRNA_delivery_original_article,10.1002/jev2.12198,CC BY-NC-ND; generated variables only; do not reproduce source figures/tables/text,supporting_EV_membrane_hybrid_siRNA_delivery_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_KLEIN_NFI_CYP_HUMAN_LIVER_PHARMACOMETABOLISM_2025,KLEIN_NFI_CYP_HUMAN_LIVER_PHARMACOMETABOLISM_2025,Transcription factors of the Nuclear Factor I family control hepatocyte differentiation and cytochrome P450 activity in human liver,human_liver_pharmacometabolism_original_article,10.1016/j.phrs.2025.107998,CC BY; not encoded in row-level synthetic tables,deferred_general_CYP_drug_metabolism_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_TANG_CUPROPTOSIS_WILSON_DISEASE_2025,TANG_CUPROPTOSIS_WILSON_DISEASE_2025,Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets,copper_liver_injury_original_article,10.1111/jcmm.70946,CC BY; generated variables only; do not reproduce source figures/tables/text,supporting_cuproptosis_copper_induced_liver_injury_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_SALIM_GALNAC_SIRNA_WB_PBPK_PD_2025,SALIM_GALNAC_SIRNA_WB_PBPK_PD_2025,Whole-Body Physiologically Based Pharmacokinetic–Pharmacodynamic Modeling for Interspecies Translation and Mechanistic Characterization of Plasma and Tissue Disposition of GalNAc-siRNAs,PBPK_PD_modeling_original_article,10.3390/pharmaceutics17091154,CC BY; generated variables only; do not reproduce source figures/tables/text,direct_GalNAc_siRNA_PK_PD_species_translation_and_off_target_distribution_module,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_VAILLANT_HBV_OLIGONUCLEOTIDE_THERAPIES_REVIEW_2022,VAILLANT_HBV_OLIGONUCLEOTIDE_THERAPIES_REVIEW_2022,"Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects",review_open_access,10.3390/v14092052,CC BY; not encoded in row-level synthetic tables,deferred_review_background_for_HBV_oligonucleotide_mechanisms,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_LACALAMITA_PID_MICROARRAY_HIGH_ORDER_PATTERNS_2025,LACALAMITA_PID_MICROARRAY_HIGH_ORDER_PATTERNS_2025,Unveiling complex patterns: An information-theoretic approach to high-order behaviors in microarray data,bioinformatics_methods_original_article,10.1371/journal.pone.0336379,CC BY; not encoded in row-level synthetic tables,deferred_optional_notebook_method_context,0,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_AGARWAL_GALNAC_SIRNA_OFFTARGET_2025,AGARWAL_GALNAC_SIRNA_OFFTARGET_2025,Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates,mechanistic_original_article_open_access,10.1089/nat.2024.0090,open access CC BY; generated variables only; do not reproduce source figures/tables/text,core_GalNAc_siRNA_RISC_AGO2_TNRC6_seed_offtarget_hepatotoxicity_module,29,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_EGLI_MANOHARAN_APPROVED_OLIGO_CHEMISTRY_2023,EGLI_MANOHARAN_APPROVED_OLIGO_CHEMISTRY_2023,"Chemistry, Structure and Function of Approved Oligonucleotide Therapeutics",critical_review_open_access,10.1093/nar/gkad067,open access CC BY-NC; generated variables only; do not reproduce source figures/tables/text,core_reference_approved_oligonucleotide_chemistry_delivery_landscape_module,16,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ARMISEN_AZD2693_PNPLA3_ASO_MASH_2025,ARMISEN_AZD2693_PNPLA3_ASO_MASH_2025,"AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials",phase1_clinical_and_preclinical_original_article_open_access,10.1016/j.jhep.2024.12.046,open access CC BY-NC-ND; generated variables only; do not reproduce source figures/tables/text,core_PNPLA3_GalNAc_ASO_precision_MASH_target_engagement_module,30,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_CROOKE_RNA_TARGETED_THERAPEUTICS_2018,CROOKE_RNA_TARGETED_THERAPEUTICS_2018,RNA-Targeted Therapeutics,perspective_article,10.1016/j.cmet.2018.03.004,freely downloadable PDF; generated variables only; do not reproduce source figures/tables/text,supporting_RNA_targeted_therapeutics_platform_mechanism_module,8,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_OLIVER_HILL_MODEL_SELECTION_NAT_2026,OLIVER_HILL_MODEL_SELECTION_NAT_2026,Model Selection in Preclinical Nucleic Acid Therapeutics Research,review_open_access,10.1038/s42003-026-09650-7,open access; generated variables only; do not reproduce source figures/tables/text,supporting_preclinical_model_selection_NAT_methods_module,8,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ALSHAER_FDA_TIDES_HARVEST_2025,ALSHAER_FDA_TIDES_HARVEST_2025,2025 FDA TIDES (Peptides and Oligonucleotides) Harvest,review_open_access,10.3390/ph19020244,open access CC BY; generated variables only; do not reproduce source figures/tables/text,supporting_current_approved_oligonucleotide_landscape_module,9,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_ABULHUSN_HSD17B13_PROTECTIVE_VARIANT_2018,ABULHUSN_HSD17B13_PROTECTIVE_VARIANT_2018,A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease,human_genetics_original_article,10.1056/NEJMoa1712191,freely downloadable PDF; generated variables only; do not reproduce source figures/tables/text,core_HSD17B13_protective_human_genetics_target_rationale_module,18,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0
PROV_MA_HSD17B13_ASO_FIBROSIS_MOUSE_2024,MA_HSD17B13_ASO_FIBROSIS_MOUSE_2024,Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model,preclinical_original_article_open_access,10.1016/j.jlr.2024.100514,open access CC BY; generated variables only; do not reproduce source figures/tables/text,core_HSD17B13_ASO_preclinical_steatosis_fibrosis_limitations_module,22,no,no,single_file_configurable_synthetic_harmonized_generator,dbbun_generated,CC BY 4.0